Last reviewed 2026-04-19 · How we verify

Metastatic human epidermal growth factor 2 positive carcinoma of breast

Approved treatments

• Enhertu · Daiichi Sankyo
  Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells.
• Enhertu · Washington D.C. Veterans Affairs Medical Center
• Margenza · Macrogenics Inc
  Margenza works by blocking the HER2/neu receptor, which is overexpressed in certain breast cancer cells, to prevent them from growing and multiplying.
• Tukysa · Seagen
  Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells.
• MARGENZA · MACROGENICS INC
• Tukysa · Pfizer
  Tukysa blocks the activity of ERBB2 and ERBB3 proteins, which are involved in cancer cell growth and spread.

Clinical guidelines

• FDA label — 2L+
  TUKYSA in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
• FDA label — 1L
  ENHERTU, in combination with pertuzumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer.
• FDA label — 2L+
  ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
• FDA label — 2L+
  ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
• FDA label — 2L+
  ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
• FDA label — 2L+
  ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
• FDA label — 2L+
  ENHERTU, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
• FDA label — 2L+
  ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Metastatic human epidermal growth factor 2 positive carcinoma of breast patent landscape — cliff calendar, originator estates, attackable patents
• Metastatic human epidermal growth factor 2 positive carcinoma of breast treatment landscape brief
• Metastatic human epidermal growth factor 2 positive carcinoma of breast treatment updates RSS

Frequently asked questions about Metastatic human epidermal growth factor 2 positive carcinoma of breast

Related

• Treatment landscape: Metastatic human epidermal growth factor 2 positive carcinoma of breast patent cliff · Metastatic human epidermal growth factor 2 positive carcinoma of breast CI report
• Treatment: Enhertu · Daiichi Sankyo
• Treatment: Enhertu · Washington D.C. Veterans Affairs Medical Center
• Treatment: Margenza · Macrogenics Inc
• Treatment: Tukysa · Seagen
• Treatment: MARGENZA · MACROGENICS INC
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing